Q-omics provides the consensus-scored HRCT1 profile across patient tissues and cancer cell-line models. HRCT1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, HRCT1 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, HRCT1 RNA expression shows 13,572 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, COAD, and TGCT as cancer lineages where HRCT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HRCT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HRCT1 survival associations across molecular data types. HRCT1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HRCT1 RNA expression–survival associations across cancer types. High HRCT1 expression shows unfavorable associations in LUSC, LGG and CHOL, but favorable associations in SKCM, UVM and KIRP. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for HRCT1 RNA expression.
This table summarizes HRCT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for HRCT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HRCT1 shows lower tumor expression in COAD, KICH, LUSC, BLCA and LUAD and higher tumor expression in LIHC. The COAD box plot shows higher HRCT1 RNA expression in normal versus tumor tissue (log2 FC = −2.695, t-test p < 0.001).
This table shows molecular features associated with HRCT1 in patient tissues and cancer cell lines. In patient samples, HRCT1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HRCT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BONE.
